Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (11365)	8/18/1999 8:47:00 PM
From: Cacaito	Respond to of 17367

Peer review? there is no need for peer review of bpi trial, Radical? No, it is the DSMB, the independent review panel (if the FDA required one, only obviated for PFE/viagra and Zona/vasomax recently), and the FDA itself. Later, the journal that will publish the work, and/or conferences will provide further peer review. Peer review for work to be published and distributed by companies (anyone can distribute pure garbage and the FDA could do nothing about it), on approved drugs because the FDA (and clinicians/scientists)have little control on the drug once is out, and even that is being challenge legally using constitutional right to speak, a judge recently call the FDA "preposterous" (no need to defend the FDA, I like their work). Peer review of procedures because there is little to control for procedures. Surgeons only control is their own judgment, lawyers and recently insurance companies paying for research to find out what work and what does not. The share price in the next few weeks will say if Xoma's actions (inactions) were right or not. If Xoma was right I will buy back at $8 to $12 (otherwise will buy back under $2 since hu1124 is worth two dollars plus the debt, and Genentech could take the company out of misery).